CRVS Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals Inc is a clinical stage biopharmaceutical company. It is engaged in development and commercialization of novel immuno-oncology therapies that are designed to harness the immune system to attack cancer cells.

$2.65
As of 05/12/2021     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  03/23/2016
Outstanding shares:  38,309,551
Average volume:  501,149
Market cap:   $98,072,451
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    221015100
ISIN:        US2210151005
Sedol:      BYP80F1
Valuation   (See tab for details)
PE ratio:   0.00
PB ratio:   0.92
PS ratio:   0.00
Return on equity:   -4.92%
Net income %:   0.00%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy